LT2014140A - New recombinant antibody against human carbonic anhydrase xii - Google Patents

New recombinant antibody against human carbonic anhydrase xii

Info

Publication number
LT2014140A
LT2014140A LT2014140A LT2014140A LT2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A
Authority
LT
Lithuania
Prior art keywords
recombinant antibody
carbonic anhydrase
anhydrase xii
produced
antibody
Prior art date
Application number
LT2014140A
Other languages
Lithuanian (lt)
Other versions
LT6331B (en
Inventor
Dovilė Dekaminavičiūtė
Milda PLEČKAITYTĖ
Daumantas Matulis
Aurelija ŽVIRBLIENĖ
Original Assignee
Vilniaus Universitetas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vilniaus Universitetas filed Critical Vilniaus Universitetas
Priority to LT2014140A priority Critical patent/LT6331B/en
Publication of LT2014140A publication Critical patent/LT2014140A/en
Publication of LT6331B publication Critical patent/LT6331B/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A new recombinant antibody that targets transmembrane enzyme carbonic anhydrase XII was produced. The expression of the enzyme increases in certain types of cancer cells. Recombinant antibody produced is a new protein, which so far has not been described in scientific literature. First, cell line (hybridomas) producing monoclonal antibody to carbonic anhydrase XII was developed. Copy DNA sequences encoding an immunoglobulin variable regions were cloned from hybridoma cells, recombinant plasmids were created and recombinant antibody expression was attained. Well-known methods, such as hybridoma technology, genetic engineering, protein purification, immunochemical analysis were used for antibody development. Recombinant antibody produced may be applied in medical and biopharmaceutical branches due to capacity to inhibit growing of cancer cells containing carbonic anhydrase XII.
LT2014140A 2014-12-12 2014-12-12 New recombinant antibody against human carbonic anhydrase xii LT6331B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LT2014140A LT6331B (en) 2014-12-12 2014-12-12 New recombinant antibody against human carbonic anhydrase xii

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2014140A LT6331B (en) 2014-12-12 2014-12-12 New recombinant antibody against human carbonic anhydrase xii

Publications (2)

Publication Number Publication Date
LT2014140A true LT2014140A (en) 2016-06-27
LT6331B LT6331B (en) 2016-11-10

Family

ID=56134742

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2014140A LT6331B (en) 2014-12-12 2014-12-12 New recombinant antibody against human carbonic anhydrase xii

Country Status (1)

Country Link
LT (1) LT6331B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018088878A2 (en) 2016-11-14 2018-05-17 주식회사 에이프로젠케이아이씨 Antibody binding to carbonic anhydrase and use thereof

Also Published As

Publication number Publication date
LT6331B (en) 2016-11-10

Similar Documents

Publication Publication Date Title
EA201992670A1 (en) METHOD FOR OBTAINING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES
MX2016015389A (en) Antibodies binding to human and cynomolgus cd3 epsilon.
MX2018013738A (en) Antibodies comprising chimeric constant domains.
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
RU2018146533A (en) ANTIBODIES TO CD40 AND WAYS OF THEIR APPLICATION
GB2549632A8 (en) Fusion protein comprising three binding domains to 5T4 and CD3
RU2014148136A (en) T-CELL COMPOSITIONS WITH LACK OF T-CELL RECEPTORS
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
MX2017001403A (en) Bispecific single chain antibody construct with enhanced tissue distribution.
EA201600276A1 (en) ANTI-IL-17-ANTIBODIES, METHOD OF THEIR RECEIVING AND METHOD OF APPLICATION
GB2509260A (en) Anti-complement C1s antibodies and uses thereof
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
NZ708182A (en) Bispecific t cell activating antigen binding molecules
MX2022014885A (en) Anti-c5 antibodies and methods of use.
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
MX2016005687A (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide.
NZ630865A (en) Anti-baff-anti-il-17 bispecific antibodies
GB201003701D0 (en) System for the expression of a protein
EA201691548A1 (en) EXPRESSING STRUCTURES AND METHODS FOR SELECTION OF CELL HOSPITALS EXPRESSING POLYPEPTIDES
TN2015000415A1 (en) Anti-cd52 antibodies
PH12017500309A1 (en) Anti-vasa antibodies, and methods of production and use thereof
EA202091569A1 (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION
BR112016028538A2 (en) glycosylated protein production process, monoclonal antibody and fusion protein production processes and fragment thereof, tnfr-fc fusion protein production process, monoclonal antibody or fusion protein production and fragment thereof
LT2014140A (en) New recombinant antibody against human carbonic anhydrase xii
MX2022014243A (en) St2 antigen binding protein.

Legal Events

Date Code Title Description
BB1A Patent application published

Effective date: 20160627

FG9A Patent granted

Effective date: 20161110

MM9A Lapsed patents

Effective date: 20201212